^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tecentriq (atezolizumab)

    i
    Other names: RO 5541267, RO 554-1267, RG7446-42, RO-5541267, MPDL3280A, RG7446, RO5541267, MPDL-3280A, RG-7446
    Company:
    Roche
    Drug class:
    PD-L1 inhibitor
    Related drugs:
    1d
    Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants (clinicaltrials.gov)
    P1, N=32, Terminated, Synlogic | N=70 --> 32 | Recruiting --> Terminated; Business reasons
    Enrollment change • Trial termination • Combination therapy • Metastases
    |
    Tecentriq (atezolizumab) • SYNB1891
    1d
    Comparison of SP263 and 22C3 pharmDx assays to test programmed death ligand-1 (PD-L1) expression in surgically resected non-small cell lung cancer. (PubMed)
    This study showed a high concordance of PD-L1 expression with the SP263 and 22C3 assays. Further studies examining the therapeutic effects of adjuvant atezolizumab are required.
    Journal • PD(L)-1 Biomarker • IO biomarker • PD(L)-1 companion diagnostic • IO Companion diagnostic
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay
    |
    Tecentriq (atezolizumab)
    1d
    A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab (clinicaltrials.gov)
    P1/2, N=200, Recruiting, Novartis Pharmaceuticals | N=39 --> 200
    Enrollment change • Combination therapy
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Lutathera (lutetium Lu 177 dotatate)
    3d
    RamAtezo-1: Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC (clinicaltrials.gov)
    P2, N=21, Completed, Washington University School of Medicine | Active, not recruiting --> Completed
    Trial completion • Checkpoint inhibition • Checkpoint block
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK mutation
    |
    Tecentriq (atezolizumab) • Cyramza (ramucirumab)
    3d
    A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma) (clinicaltrials.gov)
    P1/2, N=110, Completed, Hoffmann-La Roche | Recruiting --> Completed | N=336 --> 110 | Trial completion date: Jul 2025 --> Mar 2024 | Trial primary completion date: Jan 2025 --> Sep 2023
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Opdivo (nivolumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • tiragolumab (RG6058) • tobemstomig (RG6139)
    4d
    ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma (clinicaltrials.gov)
    P2, N=95, Active, not recruiting, ETOP IBCSG Partners Foundation | Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Mar 2024 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    EGFR mutation • EGFR L858R • EGFR T790M • EGFR G719X • EGFR S768I
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • paclitaxel • pemetrexed
    6d
    INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma (clinicaltrials.gov)
    P1/2, N=35, Active, not recruiting, Inovio Pharmaceuticals | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Tecentriq (atezolizumab) • INO-5401 • rocakinogene sifuplasmid (INO-9012)
    6d
    EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P2, N=76, Recruiting, NovoCure GmbH
    New P2 trial • Metastases
    |
    Tecentriq (atezolizumab) • gemcitabine • albumin-bound paclitaxel
    6d
    IMvigor130: Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma (clinicaltrials.gov)
    P3, N=1213, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Metastases
    |
    PD-L1 expression
    |
    cisplatin • Tecentriq (atezolizumab) • carboplatin • gemcitabine
    6d
    Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy (clinicaltrials.gov)
    P2, N=68, Recruiting, Lawrence Fong | Trial completion date: Oct 2024 --> Feb 2025 | Trial primary completion date: Oct 2024 --> Feb 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    Tecentriq (atezolizumab) • Actemra IV (tocilizumab) • etrumadenant (AB928)
    6d
    Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study (clinicaltrials.gov)
    P2, N=40, Suspended, M.D. Anderson Cancer Center | Recruiting --> Suspended
    Trial suspension • Metastases
    |
    Tecentriq (atezolizumab) • Cabometyx (cabozantinib tablet)
    6d
    Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer (clinicaltrials.gov)
    P1/2, N=280, Active, not recruiting, Kymab Limited | Trial completion date: Apr 2024 --> Aug 2024 | Trial primary completion date: Apr 2024 --> Aug 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Tecentriq (atezolizumab) • alomfilimab (SAR445256)
    6d
    Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors (clinicaltrials.gov)
    P1, N=60, Active, not recruiting, Nykode Therapeutics ASA | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Metastases
    |
    CRP (C-reactive protein)
    |
    MSI-H/dMMR
    |
    Tecentriq (atezolizumab) • VB10.NEO
    6d
    Axl as a potential therapeutic target for adamantinomatous craniopharyngiomas: based on single nucleus RNA-Seq and spatial transcriptome profiling. (PubMed, Cancer Lett)
    Additionally, the AXL inhibitor Bemcentinib effectively inhibited the proliferation organoids and enhanced the immunotherapeutic efficacy of Atezolizumab. Furthermore, neural crest-like cells were observed in the glial reactive tissue surrounding finger-like protrusions. Overall, our results revealed that the AXL might be a potentially effective therapeutic target for ACPs.
    Journal
    |
    AXL (AXL Receptor Tyrosine Kinase) • GAS6 (Growth arrest specific 6)
    |
    Tecentriq (atezolizumab) • bemcentinib (BGB324)
    8d
    The predictive value of next generation sequencing for matching advanced hepatocellular carcinoma patients to targeted and immunotherapy. (PubMed, Front Immunol)
    However, treatment of Atezolizumab and Bevacizumab appeared to provide longer OS in the high-risk group (12 months vs 9.2, 9, or 5 months for other treatments, p<0.001). The prognostic model constructed by PD-L1, TMB, TERT, and TP53 can identify aHCC patients who would benefit from targeted and immunotherapy, providing insights for the personalized treatment of HCC.
    Journal • Next-generation sequencing • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • TERT (Telomerase Reverse Transcriptase)
    |
    PD-L1 expression • TP53 wild-type
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    9d
    Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer. (clinicaltrials.gov)
    P2; Not yet recruiting --> Recruiting | Initiation date: Dec 2023 --> Apr 2024
    Combination therapy • Enrollment open • Trial initiation date • PD(L)-1 companion diagnostic • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    VENTANA PD-L1 (SP263) Assay
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Tecentriq (atezolizumab) • VB10.16
    9d
    IMCODE003: A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P2, N=260, Recruiting, Genentech, Inc. | Trial completion date: May 2029 --> Dec 2029 | Trial primary completion date: May 2029 --> Dec 2029
    Trial completion date • Trial primary completion date
    |
    Tecentriq (atezolizumab) • oxaliplatin • irinotecan • autogene cevumeran (RG6180)
    9d
    CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov)
    P1/2, N=1126, Recruiting, Amgen | Trial primary completion date: Sep 2026 --> Dec 2026
    Trial primary completion date • Combination therapy • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Mekinist (trametinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Ibrance (palbociclib) • carboplatin • paclitaxel • docetaxel • everolimus • Vectibix (panitumumab) • Lumakras (sotorasib) • pemetrexed • oxaliplatin • irinotecan • batoprotafib (TNO155) • vociprotafib (RMC-4630) • BI 1701963 • zeluvalimab (AMG 404)
    10d
    PIONEER: Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN (clinicaltrials.gov)
    P2, N=20, Completed, University Hospital, Essen | Recruiting --> Completed | Trial completion date: Dec 2024 --> Mar 2024
    Trial completion • Trial completion date
    |
    GZMB (Granzyme B)
    |
    Tecentriq (atezolizumab)
    10d
    Atezolizumab in patients (pts) with tumor mutational burden (TMB)–high tumors from the TAPISTRY trial. (ASCO 2024)
    Clinical Trial Registration Number: NCT04589845
    Late-breaking abstract • Clinical • Tumor mutational burden • PD(L)-1 Biomarker
    |
    TMB (Tumor Mutational Burden)
    |
    Tecentriq (atezolizumab)
    11d
    IMvoke010: A Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov)
    P3, N=406, Terminated, Hoffmann-La Roche | Trial completion date: Jun 2027 --> Mar 2024 | Active, not recruiting --> Terminated; Decision to terminate the study as its primary endpoint of investigator-assessed event free survival (INV-EFS) was not met at its final EFS analysis. No new safety signals were identified.
    Trial completion date • Trial termination • Metastases
    |
    Tecentriq (atezolizumab)
    11d
    Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer patients receiving nivolumab, pembrolizumab or atezolizumab therapy. (PubMed, Sci Rep)
    In conclusion, sPD-L1 measured in baseline serum samples may be associated with OS in NSCLC patients receiving anti-PD1/anti-PD-L1 treatment. Importantly, the results signify that further research is warranted to explore the clinical utility of sPD-L1 in patients treated with anti-PD-L1.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab)
    12d
    ATEZOLACC: Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab (clinicaltrials.gov)
    P2, N=189, Active, not recruiting, Gustave Roussy, Cancer Campus, Grand Paris | Recruiting --> Active, not recruiting | Trial completion date: Jul 2024 --> Apr 2025 | Trial primary completion date: Jul 2024 --> Feb 2024
    Enrollment closed • Trial completion date • Trial primary completion date • Metastases
    |
    cisplatin • Tecentriq (atezolizumab)
    12d
    BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma (clinicaltrials.gov)
    P3, N=401, Active, not recruiting, ETOP IBCSG Partners Foundation | Trial completion date: Jan 2024 --> Jun 2024 | Trial primary completion date: Jan 2024 --> Jun 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • pemetrexed
    12d
    The emerging therapies are reshaping the first-line treatment for advanced hepatocellular carcinoma: a systematic review and network meta-analysis. (PubMed, Therap Adv Gastroenterol)
    In the whole-population network meta-analysis, the newly first-line tremelimumab plus durvalumab (Tre + Du) was found to be comparable with atezolizumab plus bevacizumab (Atezo + Beva) in providing the best overall survival (OS) benefit [hazard ratio (HR) 1.35, 95% confidence interval (CI): 0.93-1.92]. Concerning OS benefits, sintilimab plus bevacizumab biosimilar (Sint + Beva), camrelizumab plus rivoceranib (Camre + Rivo), and lenvatinib plus pembrolizumab (Lenva + Pemb) appear to exhibit similar effects to Tre + Du and Atezo + Beva...With lower incidence rates of treatment-related adverse events and non-inferior efficacy compared to sorafenib, ICI monotherapies should be prioritized as a first-line treatment approach for patients who are not suitable candidates for ICI-combined therapies. PROSPERO, CRD42022288172.
    Clinical • Retrospective data • Review • Journal • Metastases
    |
    AFP (Alpha-fetoprotein)
    |
    Keytruda (pembrolizumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • sorafenib • Tyvyt (sintilimab) • Lenvima (lenvatinib) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Imjudo (tremelimumab)
    12d
    IOSI-LUNG-001: Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC (clinicaltrials.gov)
    P2, N=12, Active, not recruiting, Oncology Institute of Southern Switzerland | Recruiting --> Active, not recruiting | N=20 --> 12 | Trial completion date: Dec 2022 --> Dec 2024
    Enrollment closed • Enrollment change • Trial completion date • Metastases
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK fusion • ROS1 rearrangement
    |
    Tecentriq (atezolizumab)
    12d
    PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors (clinicaltrials.gov)
    P1, N=41, Completed, Pieris Pharmaceuticals, Inc. | Active, not recruiting --> Completed | Phase classification: P1b --> P1
    Trial completion • Phase classification • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Tecentriq (atezolizumab) • cinrebafusp alfa (PRS-343)
    12d
    BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab (clinicaltrials.gov)
    P1, N=40, Active, not recruiting, Eikon Therapeutics | Trial completion date: Mar 2024 --> Jul 2024 | Trial primary completion date: Mar 2024 --> Jul 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • IL2 (Interleukin 2) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Tecentriq (atezolizumab) • EIK1001
    12d
    IMvigor011: A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy (clinicaltrials.gov)
    P3, N=800, Recruiting, Hoffmann-La Roche | N=520 --> 800
    Enrollment change • Circulating tumor DNA
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab)
    13d
    Effect of Sex on the Oncological Outcomes in Response to Immunotherapy and Antibody-drug Conjugates in Patients with Urothelial and Kidney Cancer: A Systematic Review and a Network Meta-analysis. (PubMed, Eur Urol Oncol)
    The NMA revealed gender-specific variations in ICI and ADC responses for RCC and TCC, offering insights for personalised cancer care and addressing disparities in cancer care and outcomes.
    Retrospective data • Review • Journal
    |
    NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    Tecentriq (atezolizumab)
    16d
    Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax (clinicaltrials.gov)
    P1, N=43, Recruiting, M.D. Anderson Cancer Center | Suspended --> Recruiting | N=21 --> 43
    Enrollment open • Enrollment change • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Tecentriq (atezolizumab) • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Cometriq (cabozantinib capsule)
    16d
    BIS-Program: Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy (clinicaltrials.gov)
    P2, N=185, Recruiting, Gustave Roussy, Cancer Campus, Grand Paris | Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: Feb 2024 --> Feb 2025
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • GZMB (Granzyme B)
    |
    HER-2 positive • HER-2 overexpression • HER-2 amplification
    |
    Avastin (bevacizumab) • Herceptin (trastuzumab) • Tecentriq (atezolizumab) • Perjeta (pertuzumab)
    17d
    Rethinking strategies in SCLC: Lessons learned from tiragolumab in the SKYSCRAPER-02 study. (PubMed, Med)
    The addition of tiragolumab, an anti-TIGIT inhibitor, to chemotherapy plus atezolizumab demonstrated promising early results for lung cancer. Unfortunately, the phase 3 study SKYSCRAPER-02 did not confirm the anticipated benefit of tiragolumab combination in recalcitrant small-cell lung cancer,1 reiterating the need for a more accurate population selection in clinical trials.
    Journal
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    17d
    IMperator: A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors With Resectable Disease With Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H) (clinicaltrials.gov)
    P2, N=40, Recruiting, Hoffmann-La Roche | Not yet recruiting --> Recruiting
    Enrollment open • Tumor mutational burden
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    17d
    IBFIC: Imaging Biomarkers for Immune Checkpoint Inhibitor Treatment in Patients With Non-small Cell Lung Cancer (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Samsung Medical Center | Trial primary completion date: Dec 2023 --> Dec 2025
    Trial primary completion date • Checkpoint inhibition • IO biomarker
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab)
    18d
    ATREZZO: Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer (clinicaltrials.gov)
    P2; Trial primary completion date: Dec 2023 --> Dec 2024
    Combination therapy • Trial primary completion date • Tumor mutational burden • Metastases
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay
    |
    Herceptin (trastuzumab) • Tecentriq (atezolizumab) • vinorelbine tartrate
    18d
    A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial (clinicaltrials.gov)
    P2, N=80, Recruiting, Duke University | Not yet recruiting --> Recruiting
    Enrollment open • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • CD4 (CD4 Molecule)
    |
    TMB-H • IDH wild-type
    |
    Tecentriq (atezolizumab)
    18d
    Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations. (PubMed, JNCI Cancer Spectr)
    Derazantinib as monotherapy or in combination with atezolizumab was well-tolerated but did not show sufficient efficacy to warrant further development in mUC.
    Journal • Metastases
    |
    FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor)
    |
    Tecentriq (atezolizumab) • derazantinib (ARQ 087)
    18d
    BOUQUET: A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (clinicaltrials.gov)
    P2, N=550, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    ER (Estrogen receptor)
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • paclitaxel • Kadcyla (ado-trastuzumab emtansine) • Cotellic (cobimetinib) • Verzenio (abemaciclib) • cyclophosphamide • letrozole • ipatasertib (RG7440) • triptorelin • goserelin acetate • giredestrant (GDC-9545) • inavolisib (GDC-0077)
    19d
    A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer (clinicaltrials.gov)
    P1, N=45, Recruiting, Boehringer Ingelheim | Active, not recruiting --> Recruiting | Trial primary completion date: Aug 2024 --> Apr 2025
    Enrollment open • Trial primary completion date • Combination therapy • Metastases
    |
    SIRPA (Signal Regulatory Protein Alpha)
    |
    Erbitux (cetuximab) • Tecentriq (atezolizumab) • paclitaxel • docetaxel • capecitabine • ezabenlimab (BI 754091) • BI 765063 • BI 836880
    20d
    A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab (clinicaltrials.gov)
    P1/2, N=39, Recruiting, Novartis Pharmaceuticals | Phase classification: P1 --> P1/2
    Phase classification • Combination therapy
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Lutathera (lutetium Lu 177 dotatate)
    21d
    Peripheral T Cell Subpopulations as a Potential Surrogate Biomarker during Atezolizumab plus Bevacizumab Treatment for Hepatocellular Carcinoma. (PubMed, Cancers (Basel))
    In conclusion, TCM proportion at baseline might be a good indicator of the efficacy of Atez/Bev therapy. Furthermore, observation of increasing TEM proportions might be an early predictor of the potential clinical benefits of treatment.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)